{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:22:12Z","timestamp":1792693332368,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"am","delay-in-days":99,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/ BD \/142890\/2018"],"award-info":[{"award-number":["PD\/ BD \/142890\/2018"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cgh.2021.12.004","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T12:21:15Z","timestamp":1639052475000},"page":"2059-2073.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2634-9668","authenticated-orcid":false,"given":"Fernando","family":"Magro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diogo","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Patita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Arroja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isadora","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Tavares de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Ministro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irinia","family":"Mocanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Castela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Moleiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Roseira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nia","family":"Cancela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Portela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu\u00eds","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafalda","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Camila","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.12.004_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.cgh.2021.12.004_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2050640619887316","article-title":"Evolving therapeutic goals in Crohn\u2019s disease management","volume":"8","author":"Chateau","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.cgh.2021.12.004_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.12.004_bib4","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1016\/j.cgh.2019.02.017","article-title":"Association between level of fecal calprotectin and progression of Crohn\u2019s disease","volume":"17","author":"Kennedy","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.004_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818769076","article-title":"Emerging concepts in non-invasive monitoring of Crohn\u2019s disease","volume":"11","author":"Marlicz","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2021.12.004_bib6","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.12.004_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/00365521.2014.987809","article-title":"Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease","volume":"50","author":"Sipponen","year":"2014","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.12.004_bib8","first-page":"694","article-title":"Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: from basic science to clinical practice","volume":"2020","author":"Gisbert","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.12.004_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ecco-jcc\/jjz123","article-title":"Comparing the continuous Geboes score with the Robarts Histopathology Index: definitions of histological remission and response and their relation to faecal calprotectin levels","volume":"14","author":"Magro","year":"2020","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.12.004_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/17474124.2019.1563481","article-title":"Update on C-reactive protein and fecal calprotectin: are they accurate measures of disease activity in Crohn\u2019s disease?","volume":"13","author":"Ma","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.004_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820965790","article-title":"Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays","volume":"13","author":"Rocha","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2021.12.004_bib12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A\u00a0retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.12.004_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.2005.082909","article-title":"The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications","volume":"55","author":"Satsangi","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.12.004_bib14","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/j.cgh.2020.09.017","article-title":"Histologic features of colon biopsies (Geboes score) associated with progression of ulcerative colitis for the first 36 months after biopsy","volume":"19","author":"Magro","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.004_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/ecco-jcc\/jjy168","article-title":"Development and validation of risk matrices concerning ulcerative colitis outcomes\u2014Bayesian network analysis","volume":"13","author":"Magro","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.12.004_bib16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.12.004_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn\u2019s disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.12.004_bib18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10620-016-4397-6","article-title":"High percentage of IBD patients with indefinite fecal calprotectin levels: additional value of a combination score","volume":"62","author":"Bodelier","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.12.004_bib19","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"D\u2019Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.12.004_bib20","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity","volume":"20","author":"Lin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.12.004_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/apt.13731","article-title":"The prognostic significance of faecal calprotectin in patients with inactive inflammatory bowel disease","volume":"44","author":"Zhulina","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.12.004_bib22","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1097\/MIB.0b013e31829b2a37","article-title":"Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy","volume":"19","author":"De Vos","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.12.004_bib23","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.crohns.2013.07.005","article-title":"High C-reactive protein in Crohn\u2019s disease patients predicts nonresponse to infliximab treatment","volume":"8","author":"Magro","year":"2014","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.12.004_bib24","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.cgh.2011.02.008","article-title":"Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn\u2019s disease","volume":"9","author":"J\u00fcrgens","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.12.004_bib25","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.12.004_bib26","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41598-020-57508-7","article-title":"Serum C-reactive protein and albumin are useful biomarkers for tight control management of Crohn\u2019s disease in Japan","volume":"10","author":"Shiga","year":"2020","journal-title":"Sci Rep"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521012982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521012982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:38:05Z","timestamp":1761543485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521012982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1542356521012982"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.12.004","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 Years","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}